Rasagiline
- Generic Name
- Rasagiline
- Brand Names
- Azilect, Rasagiline Mylan, Rasagiline ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H13N
- CAS Number
- 136236-51-6
- Unique Ingredient Identifier
- 003N66TS6T
- Background
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
- Indication
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
- Associated Conditions
- Parkinson's Disease (PD)
Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 252
- Registration Number
- NCT01879241
- Locations
- 🇩🇪
Department of Neurology, Universty of Bonn, Bonn, Nordrhrein-Westfalen, Germany
🇩🇪Department of Neurology, TU Dresden, Dresden, Sachsen, Germany
🇩🇪Department of Neurology, University of Halle-Wittenberg, Halle/Saale, Sachsen-Anhalt, Germany
Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Richard Barohn, MD
- Target Recruit Count
- 80
- Registration Number
- NCT01786603
- Locations
- 🇺🇸
St. Louis University, Saint Louis, Missouri, United States
🇺🇸Columbia University, New York, New York, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study
- Conditions
- Drug-naïve Patients With Parkinson's DiseaseApathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Target Recruit Count
- 50
- Registration Number
- NCT01765257
- Locations
- 🇫🇷
CHU Clermont-Ferrand, Clermont-Ferrand, France
Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Chongqing Fortune Pharmaceutical Co., Ltd.
- Target Recruit Count
- 268
- Registration Number
- NCT01736891
- Locations
- 🇨🇳
CN006, Luzhou, China
🇨🇳CN003, Guilin, China
🇨🇳CN002, Chengdu, China
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT01723228
- Locations
- 🇺🇸
Teva Investigational Site 003, Chicago, Illinois, United States
🇺🇸Teva Investigational Site 016, La Jolla, California, United States
🇺🇸Teva Investigational Site 004, Irvine, California, United States
Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 12
- Registration Number
- NCT01652313
- Locations
- 🇨🇳
CN001, Beijing, China
Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 130
- Registration Number
- NCT01556165
- Locations
- 🇨🇳
CN005, Guangzhou, China
🇨🇳CN011, Chengdu, China
🇨🇳CN004, Hangzhou, China
Effect of Rasagiline on BIA 9-1067 Pharmacokinetics
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 25
- Registration Number
- NCT01532141
- Locations
- 🇫🇷
BIOTRIAL, Rennes, France
Effect of BIA 9-1067 on Rasagiline Pharmacokinetics
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 24
- Registration Number
- NCT01532128
- Locations
- 🇫🇷
BIOTRIAL, Rennes, France
A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2015-12-16
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 34
- Registration Number
- NCT01497652
- Locations
- 🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.